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In a recent report published in PNAS, Gellman and coworkers describe the design, characterization, and
potent activity of a/b-peptides that mimic a long a helix involved in HIV viral entry.
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PreviewsProtein-protein interactions are intrinsic
to many biological processes, from signal
transduction to cell death, and misregula-
tion of these interactions is implicated in
many diseases. As such, these interac-
tions are potential targets for drug dis-
covery. However, the disruption of pro-
tein-protein interactions is a difficult
challenge because the protein interfaces
often occupy large surface areas and
lack deep cavities amenable for small-
molecule binding (Arkin and Wells, 2004).
A broad effort in the organic andmedic-
inal chemistry community to develop suit-
able ligands to target protein-protein
interactions has focused on fragment-
based screening and the synthesis of
natural products and natural product-like
libraries (Stockwell, 2004). A complemen-
tary effort has centered on a rational-
design approach that seeks to adapt
protein recognition principles utilized by
nature. The examination of the structural
features of complexes of proteins with
other biomolecules reveals that proteins
tend to interact with partners via folded
subdomains, or protein secondary struc-
tures. a helices constitute the largest
class of protein secondary structures,
and play a major role in mediating pro-
tein-protein interactions. Peptides adopt
stable helical conformation in the context
of proteins, but isolated peptides in solu-
tion rarely retain their biologically relevant
structure. The chemical biology commu-
nity has focused much of its attention on
studying different approaches to either
stabilize the a-helical conformation in
peptides or mimic this domain with non-
natural scaffolds. These approaches can
be divided into three general categories:
helix stabilization, helical foldamers, and
helical surface mimetics (Henchey et al.,
2008). Helix stabilizing methods based
on side-chain crosslinks and hydrogen-
bond surrogates pre-organize amino
acid residues and initiate helix formation;miniproteins that display helical domains
are also part of this category. Helical fol-
damers are oligomers composed of non-
natural amino acid residues capable of
adopting conformations similar to those
found in natural proteins. Helical surface
mimetics utilize conformationally re-
stricted scaffolds with attached functional
groups that resemble the i, i+4, i+7
pattern of side chain positioning along
the face of an a helix.
TheworkofGellmanandothers focuses
on b-peptide foldamers (Figure 1), which
are well-established mimics of a helices
(Gellman, 1998; Seebach and Gardiner,
2008). Multiple methods for controlling
the helical structure of b-peptides have
been described. The Gellman group has
pioneered the use of cyclic b-amino acid
residues to lock the oligomer backbone
into favorable positions. Constraining
the desired Ca-Cb torsional angles in
cyclic compounds (e.g., trans-2-aminocy-
clopentanecarboxylic acid (ACPC) and
trans-3-Aminopyrrolidine-4-carboxylic
acid (APC); Figure 1A) improves helicity by
reducing flexibility (Gellman, 1998). Other
approaches for stabilizing the b-peptide
conformation include the insertion of
favorable salt-bridging interactions along
one face of the helix and control of the
helical macrodipole (Kritzer et al., 2005).
More recently, a-, b- and cyclic b-amino
acid residues were combined to create
heterogeneous backbones with a diverse
projection of side-chain functionality
(Horne and Gellman, 2008). The ability of
foldamers to take on a variety of helical
shapes is advantageous in the design of
therapeutics that better imitate protein
secondary structures (Goodman et al.,
2007).
Perhaps the greatest benefit of
b-peptides is their inherent proteolytic
stability. The b-peptide backbone is not
recognized by common proteases, and
the b residues in a/b-peptides offerChemistry & Biology 16, September 25, 200substantial protection to neighboring
amides from proteolytic cleavage (Horne
et al., 2009).
In the current manuscript, Horne et al.
(2009) created a panel of peptides con-
taining a-, b- and cyclized b-amino acids
that potently inhibit HIV entry. Viral entry
is facilitated by conformational changes
that HIV membrane protein gp41 un-
dergoes to adopt a six-helix bundle
during the fusion of the host and viral
membranes. The six-helix bundle consists
of three helices from the C-terminal
heptad repeat domain and three helices
from theN-terminal heptad repeat domain
(Chan et al., 1997). Prevention of bundle
formation using a-peptides (or mimics
thereof) derived from the C-terminal
region is central to anti-HIV entry drug
design efforts. One drug in current use,
enfuvirtide (Fuzeon), is a 36-amino acid
a-peptide comprised of residues from
the C-terminal region of gp41. As enfuvir-
tide is composed solely of a-amino acids,
it is susceptible to protease degradation
and therefore can be highly unstable as
a therapeutic agent.
Discoveryofpotentnonnatural, peptide-
based gp41 mimics or small molecules
capable of disrupting six-helix bundle
formation has been a difficult challenge.
Gellman and coworkers began their
a/b-peptide designs bymimicking a previ-
ously described a-peptide helix (Horne
et al., 2009). Acyclic b3-amino acid sub-
stitution into the a-peptide sequence
provided modest inhibitors with in vitro
activity in the micromolar range. Replace-
ment of key acyclic b-residues with
ACPC and APC resulted in rigidified
chimeric a/b-peptides with a remarkable
380-fold binding enhancement. The opti-
mization studies provided highly effective
constructs with low nanomolar activities
in cell-cell fusion and HIV anti-infectivity
assays. Importantly, helical propensity in
a/b-peptidescorrelatedwell with inhibitory9 ª2009 Elsevier Ltd All rights reserved 919
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PreviewsFigure 1. a Helix and a/b-Peptide Foldamers Array Side Chain Functionality in Similar
Fashion
(A) Backbone sequences of a, b, and a/b helices, and structures of cyclic b-residues.
(B) Comparison of the a, and a/b helices (PDB codes 2ZTA and 3C3F).potency and resistance against proteolytic
degradation.
The current work highlights the molec-
ular design strategy employed byGellman
and coworkers (Horne et al., 2009) to
create faithful mimics of the a helix that
are endowed with conformational and
proteolytic stability. Structural studies
suggest that subtle changes in the back-
bone composition can significantly affect920 Chemistry & Biology 16, September 25,the superhelical twist of the foldamer
helix. Addressing these critical observa-
tions will help build a comprehensive
understanding of the relationship bet-
ween sequence, structure, and function
in foldamers. The mechanism used by
the HIV virus to enter cells is also em-
ployed by other Class I viruses to target
host cells (Dimitrov, 2004). Success of
the outlined strategy suggests that a/b2009 ª2009 Elsevier Ltd All rights reservedhelices may be effective scaffolds for the
generation of potent inhibitors or antigens
against these viruses.
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